Advertisement

Topics

Latest Respiratory NewsRSS

10:27 EDT 20th September 2017 | BioPortfolio

Global Nebulizers Market Research Report 20112023 [Report Updated: 31082017] Prices from USD $2200

SummaryNebulizer is a medical device which converts the drug into mist and delivers it directly to the lungs. The technique of nebulization is commonly used for the treatment of respiratory diseases including asthma, cystic fibrosis and COPD. Various devices are used for nebulization. Devices that are rechargeable and electrically powered are the most widely usedThe global Nebulizers market will r...

Dr. Patrick Cieplak Educates Community on Signs of Gingivitis in La Plata, MD, During National Gum Care Month

Dr. Patrick Cieplak supports National Gum Care Month by teaching patients common gum disease symptoms to be aware of, including bleeding gums and chronic bad breath. Dr. Cieplak is experienced in diagnosing and treating gingivitis in La Plata, MD, which is the earliest stage of periodontal disease. La Plata, MD (PRWEB) September 20, 2017 In support of National Gum Care Month, Dr. Patrick Cieplak ...

Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug

LEXINGTON, Mass., Sept. 20, 2017 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two important new patents from the United States Patent and Trademark Office. The first new patent expands the potential of Pulmatrix's technology for...

GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the ...

FDA OKs Glaxo's inhaler, first one to combine 3 medicines

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of Trelegy Ellipta, developed jointly by GlaxoSmithKline PLC and Innoviva Inc. It contains three widely used types of medicine to prevent - rather than treat -flare-ups of the life-threatening breathing diso...

Global Anesthesia Video Laryngoscope Market Research Report 20112023 [Report Updated: 28082017] Prices from USD $1960

SummaryAnesthesia Video Laryngoscope is a kind of Laryngoscope which combines video system to assist the traditional Laryngoscope operation. While traditional Laryngoscope operation requires training to be an experienced laryngoscopist and tracheal intubator, in case of video laryngoscopy VL, even the novices can successfully do laryngoscopy and intubate the trachea.The global Anesthesia Video Lar...

Propeller Health presents data on asthma and COPD at the European Respiratory Society International Congress

MADISON, Wis., Sept. 19, 2017 /PRNewswire/ -- Today, Propeller Health released the results from three new asthma and COPD studies presented last week at the European Respiratory Society International Congress (ERS) in Milan, Italy. The five-day event is the world's largest respiratory health meeting. The company shared interim results on the feasibility and clinical impact of a digital h...

Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference

DUBLIN, Sept. 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET. The conference will be held September 25 - 27 at the Intercontinental New York Barclay Hotel. A live broadcast will be available b...

Dry powder development: Vectura’s BI alternative backed by Pulmatrix

Vectura has advanced plans to develop a dry powder inhaler to treat patients with chronic obstructive pulmonary disease (COPD) for the US market.

Indianapolis Manufacturer Welcomes New Medical Director

INDIANAPOLIS, Sept. 19, 2017 /PRNewswire/ -- Pulmodyne, a global manufacturer of high quality respiratory, and emergency airway products, has hired Dr. Brett Greenfield to serve as their new Medical Director. In this new role, Dr. Greenfield will provide medical direction in support of current lines, and new product development. With his extensive background, Pulmodyne feels he will help to suppor...

Swine flu may double risk for type 1 diabetes

Norwegians aged 30 years or younger infected with the H1N1 influenza virus during the pandemic were twice as likely to develop type 1 diabetes vs. the general population, according to findings presented at the European Association for the Study of Diabetes Annual Meeting. “Our findings support a suggested role of respiratory infections in the etiology of type 1 diabetes,” Paz Lopez-Doriga Ruiz...

IDbyDNA and ARUP Laboratories Introduce Explify Respiratory: Breakthrough Technology to Diagnose Pneumonia Caused by Previously Undetected Pathogens

Metagenomics test identified pathogens missed by conventional lab tests in 44 percent of immunocompromised children treated for respiratory infection ARUP Laboratories and

GSK outlines multi-site plan for new US COPD med Trelegy Ellipta

The APIs for the newly US approved three-in-one COPD drug Trelegy Ellipta will be made at facility in Singapore according to GSK.

New Documentary Film Shines Light on Physical and Emotional Impact of COPD

RIDGEFIELD, Conn., Sept. 19, 2017 /PRNewswire/ -- A new documentary film, Clear the Air: Opening Up About COPD, which premiered today online, presents the compelling stories of three people who are living with chronic obstructive pulmonary disease (COPD), a debilitating lung disease that affects more than 15 million Americans and is the third leading cause of death in the United States. ...

Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN

SANTA CLARA, Calif., Sept. 19, 2017 /PRNewswire/ -- Based on its recent analysis of the respiratory care market, Frost & Sullivan recognizes Ventec Life Systems with the 2017 North American Frost & Sullivan Award for New Product Innovation. Ventec Life Systems received Food and Drug Administration (FDA) clearance for its portable unified respiratory system, VOCSN, in April 2017. The innova...

GSK's respiratory business boosted by lung drug approval

The three-in-one inhaler should help GlaxoSmithKline stay competitive in respiratory disease as rival therapies erode sales of its blockbuster drug Advair.

Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

DUBLIN, Sept. 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA® inhaler (previously referred to as the Closed Triple), for the long-term, once-daily, ma...

Us Fda approves GSK's three-in-one drug inhaler for Copd

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease . FILE PHOTO: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

GlaxoSmithKline Investors Rejoice After Winning a Much-Needed OK for Triple COPD Drug Inhaler

  Life Sciences Jobs   ...

Theravance Biopharma Highlights Approval Of Trelegy Ellipta (Closed Triple) As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The U.S.

  Life Sciences Jobs   ...

GlaxoSmithKline Release: Trelegy Ellipta Approved As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With Copd In The U.S.

  Life Sciences Jobs   ...

Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chro...

Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)

DUBLIN, Ireland, Sept. 18, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for the Closed Triple (the triple...

Mologic Receives CE Mark Approval for BVPro Point-of-Care Diagnostic for Patients with Bacterial Vaginosis.

Signs Distribution Agreement with Hitado for Germany Bedfordshire, UK, Sept 18th, 2017: Mologic Ltd, which develops powerful, personalised diagnostics to improve the lives of patients, today announced it has received CE mark approval for BVPro®, a rapid point-of-care test for patients presenting with symptoms of vaginosis. The Company also announced the commercial launch of the test, a...

Cough Pipeline Review, H2 2017 [Report Updated: 29082017] Prices from USD $2000

Cough Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough Pipeline Review, H2 2017, provides an overview of the Cough Respiratory pipeline landscape.Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough also known as pertussis are distinct types ...

Quick Search
Advertisement
 

review and buy Respiratory market research data and corporate reports here